In T2DM, impaired insulin signaling hinders upstream AKT from phosphorylating the Ser9 of GSK‐3β, resulting in increased GSK‐3β activity that promotes AD‐like pathologies [21, 22, 23]. This evidence concerns the gene GSK3B and Alzheimer disease.